ADMA Stock Analysis: Buy, Sell, or Hold?
ADMA - ADMA Biologics, Inc.
$8.38
0.11 (1.33%)
▲
5d:
+6.35%
30d:
-23.89%
90d:
-47.46%
HOLD
MODERATE Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
5 traders called ADMA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ADMA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ADMA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$28.60
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$17.76
52.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $8.38, which is considered oversold relative to its 30-day fair value range of $8.86 to $11.02. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.9) compared to its historical average (13.9). Remarkably, the market is currently pricing in an annual earnings decline of 17.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ADMA is in a strong downtrend. Immediate support is located at $7.50, while resistance sits at $10.56.
Market Sentiment: ADMA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $16.75 (+99.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ADMA is in a strong downtrend. Immediate support is located at $7.50, while resistance sits at $10.56.
Market Sentiment: ADMA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $16.75 (+99.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.86 -
$11.02
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding ADMA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 99.9% below Wall St target ($16.75)
Trading Range Analysis
30-Day Trading Range
$8.86 -
$11.02
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.50
Resistance Level
$10.56
Current Trend
Strong Downtrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.93
Wall Street Target
$16.75
(+99.9%)
Revenue Growth (YoY)
15.9%
Earnings Growth (YoY)
-52.8%
Profit Margin
32.4%
Valuation Discount vs History
-17.0% cheaper
PE vs Historical
7.9 vs 13.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-17.0%
(market-implied from PE analysis)
1-Year Target
$7.54
(-10%)
2-Year Target
$6.79
(-19%)
3-Year Target
$6.11
(-27%)
3-Yr Target (if PE normalizes)
(PE: 8→14)
$10.71
(+28%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 27.3%)
$48.19
(+475%)
Base:
(SPY PE: 7.9, Growth: 27.3%)
$17.29
(+106%)
Bear:
(PE: 6.7, Growth: 27.3%)
$14.70
(+75%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 12.16 | Current EPS (TTM): $0.68
Bull Case
$14.14
(+69%)
Analyst growth 55.4%, PE expands to 13.4
Base Case
$12.85
(+53%)
Market implied 55.4%, PE stable at 12.2
Bear Case
$5.62
(-33%)
Severe decline -20.0%, PE contracts to 10.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.9 to 13.9
Stabilization Target:
$14.69
(+75.3%)
PE Expansion Potential:
+75.3%
Share & Embed Analysis
Last updated: May 18, 2026 10:55 PM ET
Data refreshes hourly during market hours. Next update: 11:55 PM
Data refreshes hourly during market hours. Next update: 11:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Kaitlin M Kestenberg-Mes…
SELL
10096 shares
2026-03-09
Steve Elms
BUY
7000 shares
2026-03-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$90 | 50 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 56 HOLD |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
